Search for: "ASTRAZENECA AB V APOTEX"
Results 1 - 16
of 16
Sorted by Relevance
|
Sort by Date
26 May 2012, 8:41 pm
Apotex Pty Ltd v AstraZeneca AB [2011] FCA 1520 (14 December 2011) Apotex Pty Ltd v AstraZeneca AB (No 2) [2012] FCA 142 (28 February 2012) Watson Pharma Pty Ltd v AstraZeneca AB [2012] FCA 200 (9 March 2012) Apotex Pty Ltd v AstraZeneca AB (No 3) [2012] FCA 265 (23 March 2012) AstraZenenca’s cholesterol drug CRESTOR will remain without generic competition… [read post]
11 Mar 2012, 3:32 pm
Apotex Pty Ltd v AstraZeneca AB (No 2) [2012] FCA 142 (28 February 2012) Watson Pharma Pty Ltd v AstraZeneca AB [2012] FCA 200 (9 March 2012) Interlocutory injunctions – prima facie case – balance of convenience – whether additional evidence provides grounds to vary previous findings At least five Australian pharmaceutical manufacturers are now ready to launch generic versions of cholesterol-lowering drug CRESTOR,… [read post]
7 Mar 2012, 5:32 am
Apotex Pty Ltd v AstraZeneca AB [2011] FCA 1520 (14 December 2011) Interlocutory injunctions – prima facie case – balance of convenience – relevance of delay by patentee, complexity of proceedings, and parties’ conduct and obligations In the first Federal Court decision to follow the ruling of the Full Court in Samsung v Apple (see Samsung v Apple – A Closer Look at the Appeal Decision) Justice Rares has granted a… [read post]
7 Apr 2015, 11:49 am
We previously affirmedthe district court’s decision in an earlier phase of the samelitigation holding that Apotex had infringed certainpatents held by AstraZeneca AB and related parties(collectively, “Astra”). [read post]
13 Jan 2009, 8:41 am
AstraZeneca AB: This case involves a burden of proof. [read post]
18 May 2015, 5:55 am
.' Astrazeneca AB v. [read post]
11 Apr 2016, 5:26 am
.' Astrazeneca AB v. [read post]
5 Dec 2013, 7:21 am
Astrazeneca AB, et al v. [read post]
22 May 2015, 10:38 am
., Paul Inman and Ailsa Carter, who have summarised a decision from the Court of Appeal yesterday, AstraZeneca AB & Anor v KRKA dd Novo Mesto & Anor [2015] EWCA Civ 484. [read post]
20 Apr 2012, 10:36 am
McGrath In its recent decision in AstraZeneca Pharmaceuticals LP v. [read post]
12 Oct 2010, 8:56 pm
Highlights this week included: Aricept(Donepezil) –US: Declaratory judgment jurisdiction for subsequent Paragraph IV filers: Teva Pharmaceuticals USA, Inc. v. [read post]
10 Aug 2011, 4:30 am
(FDA Law Blog) Lipitor (Atorvastatin) – The fight for Atorvastatin: further news (The SPC blog) Nexium (Esomeprazole magnesium) – US: Patent infringement complaint filed following a Paragraph IV certification: Astrazeneca AB et al. v. [read post]
22 Dec 2010, 3:01 am
Pfizer Health AB & Anor v Schwarz Pharma AG & Ors (PatLit) US: Briefing updates – AMP v. [read post]
23 Sep 2016, 7:12 am
See AstraZeneca AB v. [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
